PMC10032428_01
PGM1 monitoring index (PGM1-TMI)

 of transferrin biomarkers for select patients in the case series.. For patients 1, 3, and 5, the PGM1-TMI pre-galactose treatment (gray bars)
and at last clinical follow-up (patterned bars) is shown demonstrating
improvement in transferrin glycosylation. Patients 2 and 4 were excluded.
Patient 2 discontinued galactose treatment. Patient 4 did not have a
pretreatment sample available for analysis. Refer to Supplementary
Information for more details.
10.1177_26330040221150269-fig1.jpg
PMC10032428_05_10.1177_26330040221150269-fig1.jpg
fig1-26330040221150269
Serum transferrin glycosylation improved on D-gal as well (Figure 1).
PMC10032428_02
PMC10032428_03
PGM1 monitoring index (PGM1-TMI)

 of transferrin biomarkers for select patients in the case series.. For patients 1, 3, and 5, the PGM1-TMI pre-galactose treatment (gray bars)
and at last clinical follow-up (patterned bars) is shown demonstrating
improvement in transferrin glycosylation. Patients 2 and 4 were excluded.
Patient 2 discontinued galactose treatment. Patient 4 did not have a
pretreatment sample available for analysis. Refer to Supplementary
Information for more details.
10.1177_26330040221150269-fig1.jpg
PMC10032428_05_10.1177_26330040221150269-fig1.jpg
fig1-26330040221150269
Serum transferrin glycosylation improved on D-gal as well (Figure 1).
PMC10032428_04
PMC10032428_05
PGM1 monitoring index (PGM1-TMI)

 of transferrin biomarkers for select patients in the case series.. For patients 1, 3, and 5, the PGM1-TMI pre-galactose treatment (gray bars)
and at last clinical follow-up (patterned bars) is shown demonstrating
improvement in transferrin glycosylation. Patients 2 and 4 were excluded.
Patient 2 discontinued galactose treatment. Patient 4 did not have a
pretreatment sample available for analysis. Refer to Supplementary
Information for more details.
10.1177_26330040221150269-fig1.jpg
PMC10032428_05_10.1177_26330040221150269-fig1.jpg
fig1-26330040221150269
Serum transferrin glycosylation improved on D-gal as well (Figure 1).